MedTrace Logo

Oral OKT3 for the Treatment of Active Ulcerative Colitis

NCT01287195 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-02-11

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and efficacy of orally delivered short-term OKT3 in participants with active ulcerative colitis.

Conditions

Interventions

DRUG

Oral OKT3

1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days

DRUG

Omeprazole

20 mg Omeprazole will be given orally to participants once daily for 30 days

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Scott Snapper, MD, PhD · Brigham and Women's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-07
Primary Completion
2013-05-02
Completion
2013-05-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01287195 on ClinicalTrials.gov